Information Provided By: 
Fly News Breaks for September 18, 2017
BEAT
Sep 18, 2017 | 09:12 EDT
Dougherty analyst Gene Mannheimer refuted the "short" report published by a boutique research firm regarding BioTelemetry, stating that the report doesn't appear to consider an anticipated 2% reimbursement increase that should help the company see 10% growth in 2018 even if volumes fall short of double-digit growth. The analyst, who expects volume increases from both core BioTelemetry and newly acquired LifeWatch in absolute terms, maintains a Buy rating and $40 price target on the stock, which declined about 12% on Friday.
News For BEAT From the Last 2 Days
There are no results for your query BEAT
